Oslo, Norway, 1 July 2021

Nordic Nanovector ASA (OSE: NANOV) announces that Ms. Malene Brondberg has been
appointed interim Chief Executive Officer with immediate effect.

Ms. Brondberg, who is currently the Company's Chief Financial Officer, replaces
Peter Braun who has decided to leave his position with Nordic Nanovector for
personal reasons. Ms. Brondberg will continue in her role as CFO. The Board has
initiated a search for a new CEO.

Ms. Brondberg joined Nordic Nanovector as Vice President Investor Relations in
February 2018 and was appointed CFO in May 2020. She brings over 20 years'
operational experience in the financial services sector from a career that
included being Global Head of Research, managing a team of over 65 people, and a
member of the Executive Committee of the Nordic investment bank ABG Sundal
Collier. Ms. Brondberg has also worked as a management consultant within the
financial sector, acting as an advisor in relation to investor relations and
funding. In addition, she has held interim CEO, COO and Head of
Compliance/HR/Finance management positions at several companies.

Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: "The Board is
pleased to appoint Malene Brondberg as Nordic Nanovector's interim CEO. As CFO,
Malene has proved to be a highly competent leader and has played a key role in
the overall management of the business, including raising the funding needed to
progress the on-going PARADIGME study with Betalutin®. On behalf of the Board, I
would like to wish Peter well in his future endeavours."

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31 614672518
Email: janegberts@aol.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 207 638 9571
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
release was published by Malene Brondberg, Interim CEO and CFO, Nordic
Nanovector ASA, on Thursday 1 July 2021 at 07:30 CEST.